最近,美国一家生物技术公司与日本一家制药公司宣布,他们开发的治疗阿尔茨海默症(Alzheimer's disease,简称AD)的药物已经通过临床测试,正在等待美国食品和药物管理局(FDA)批准。
《经济学人》2019年10月26日这一期里面 Fabulous or futile? 这篇文章,就讲到我们应该如何去看待这一事件。
America's Food and Drug Administration, which will decide whether to give aducanumab the go-ahead, will of course be aware of the conventions concerning statistical power, and will make its decision in light of that awareness. There must, though, be a temptation, given the magnitude of the problem of Alzheimer's (in America alone there are almost 6m cases), and the absence of alternative treatments, to give a green light to something that might work, in the hope that it does work. Which will make heroes out of everyone involved if it turns out to be correct-and villains if it does not.
- but we're in a hurry.
联系客服